E Weak Markets - Yom HaShoah

*Tomra is still in the same twist with its TMRAF at $47.05, up 1.23% which the ADR, TMRAY is down 1.5% at $45.81.

*Alimentation Couche-Tard ANCUF is up 2.82% today after it announced it will sell 355 non-strategic sites last month. The Quebec firm was hit with some negative analyst reports but we opted to hang in there despite a poor quarterly. Now shopping and driving are reviving in North America boosting the sector.

*Chinese NIO announced its 100,000th vehicle sale in China but the stock fell 4.9% to $38.05 because China is raising interest rates to cool off the economy, while also attacking independent companies. Berkshire Hathaway's pick BYD, which we used to own when it was tipped by Fei Chen, sold twice as many electric cars as Nio and also makes hybrid cars. However, the sector was weak because of a new debt offering by Li Auto and market skepticism about Niu Tech's plans to sell its 2-wheel electric kick scooter in the US and Europe.

*Coupang lost traction because Sea Ltd Southeast Asia Amazon may be a threat to Korean CPNG.

Drugs

*Britain ordered Astra-Zeneca to limit the use of its vaccine developed by Oxford University to inoculate people under 30 after the European Medicines Agency yesterday revealed that there may be a link between the jab and rare brain blood clots. AZN halted UK trials of the vaccine for children 6 to 17 years old. The share is down 0.85%.

*Glaxo stock rose to fill the gap, up 0.33%. GSK.

*The US Center for Disease Control now thinks that the UK B.1.1.7 variant is dominant in the US as well and may account for the nearly 20% increase in the 7-day average of cases vs the 14-day level.

*AbCellera Biologics of Canada reported that its bamlanivimab antibody therapy is highly potent against Covid-19 by blocking virus replication in the upper airway by binding to the spike protein. It should be administered with a second antibody to expand virus protection. It won in only 90 days US FDA approval as the 1st monoclonal antibody to treat the virus and is now approved in 15 countries. ABCL is up 1.83%. Zymeworks is down 1.5% for no reason except that ZYME is not ABCL.

View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.